|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
1992-7-31
|
|
pubmed:abstractText |
Rifampin is recommended as a prophylactic treatment for intimate contacts of young children who develop invasive infections with Haemophilus influenzae type B (Hib). A 4-day course of rifampin (20 mg/kg of body weight per day, not to exceed 600 mg as a maximum single daily dose) is 95% effective in eradicating pharyngeal colonization with Hib, thus effectively reducing the risk of both associated patients and recurrent illness in index patients less than 2 years old. This study compares rates of eradication of pharyngeal colonization with Hib for 2- and 4-day courses of rifampin therapy. One hundred sixty-three patients with Hib infection were treated at Children's Hospital of Pittsburgh between January 1986 and December 1988; prophylaxis was recommended for 128. Participating families were randomized to receive either 2- or 4-day therapy. Throat swabs were obtained from contacts prior to therapy. Repeat cultures were obtained from colonized contacts 2 days after completing rifampin and again on all contacts 7 to 10 days after completing therapy. Of 68 participating families, 34 received 2-day and 34 received 4-day therapy with rifampin. Twenty-two of 24 colonized contacts in the 2-day group and 17 of 18 in the 4-day group had negative cultures for Hib on follow-up. Two-day therapy with rifampin appears to be as effective as 4-day treatment in the eradication of Hib pharyngeal colonization.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/1622163-302288,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1622163-3114708,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1622163-312483,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1622163-312927,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1622163-3485373,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1622163-3489921,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1622163-3874293,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1622163-3900905,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1622163-5764453,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1622163-6337760,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1622163-6368889,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1622163-6967580,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1622163-6967587,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1622163-7000999,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1622163-7009819
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0066-4804
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
36
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
545-7
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:1622163-Administration, Oral,
pubmed-meshheading:1622163-Adolescent,
pubmed-meshheading:1622163-Child,
pubmed-meshheading:1622163-Child, Preschool,
pubmed-meshheading:1622163-Dose-Response Relationship, Drug,
pubmed-meshheading:1622163-Female,
pubmed-meshheading:1622163-Haemophilus Infections,
pubmed-meshheading:1622163-Haemophilus influenzae,
pubmed-meshheading:1622163-Humans,
pubmed-meshheading:1622163-Infant,
pubmed-meshheading:1622163-Male,
pubmed-meshheading:1622163-Pharynx,
pubmed-meshheading:1622163-Random Allocation,
pubmed-meshheading:1622163-Rifampin
|
|
pubmed:year |
1992
|
|
pubmed:articleTitle |
Duration of rifampin chemoprophylaxis for contacts of patients infected with Haemophilus influenzae type B.
|
|
pubmed:affiliation |
Department of Pediatrics, University of Pittsburgh School of Medicine, Pennsylvania.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial
|
